Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $210
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $207 to $210.
Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $207 to $210.